云南白药财务报表全英分析报告.ppt

The analysis of Yunnan baiyao Group Co., Ltd 01 03 PART PART 02 PART Business Analysis Finance Analysis Financial Forecasting and Valuation Catalogue A B ●The brief introduction Yunnan baiyao Group Co., Ltd.(stock code 000 538), is one of the most well-recognized chinese pharmaceutical enterprises in Yunnan Province which has the largest scale, best brand, and most abundant strength abilities. Yunnan Baiyao was successfully formulated by Mr. Qu Huanzhang in 1902, which was honored as “trauma panacea”. ● Major products Business Analysis series Yunnan baiyao phytobiological medicine health products modern medicine …… P ● The implementation of new medical reform will brings a large demand for medicine. ● There are an increasing number of medical policies and laws to lay down strict standard to the medicine quality and price. ● After WTO,many international companies will expand new market in China. E ● The development of economy and the stability of economic policy ● The government carries out series of policies to promote the adjustment of structure of medicine manufacturing S ● The Aging population and the improvement of people’s income will bring a large demand for medicine. T ● Nowadays,many medical companies is mostly focus on the low level of preparation so it’s urgent to improve the research and development in biotechnology ,on-patent drugs and new preparations. PEST analysis ● business environment S ● one of the ten key large-scale enterprises in Yunnan province ● a good governance structure, management mechanism and incentive systems ● has passed the GMP certification and has a large potential in developing new market and products. W ● the production series is too dull and lack of the product structure adjustment ● the market share overseas is too small O ● The world is facing with the Aging population,which causes